p14ARF expression in invasive breast cancers and ductal carcinoma in situ – relationships to p53 and Hdm2 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-07-29

AUTHORS

SB Vestey, C Sen, CJ Calder, CM Perks, M Pignatelli, ZE Winters

ABSTRACT

INTRODUCTION: p14ARF stabilises nuclear p53, with a variable expression of p14ARF mRNA in breast cancers. In vitro, nuclear p14ARF binds Hdm2 to block Hdm2-dependent nucleocytoplasmic shuttling of p53, which is required before cytoplasmic degradation of p53. p14ARF is negatively regulated by p53 and through p53-independent pathways. No studies have yet examined levels of p14ARF protein expression in breast cancer and their relationship to Hdm2/p53 immunoreactivity or subcellular localisation. Previously, immunohistochemical expression of cytoplasmic p14ARF, p53 and Hdm2 has been described. HER-2 (c-erbB2/neu) predicts prognosis and interacts with the p14ARF/Hdm2 pathway to inactivate p14ARF and to influence Hdm2 activity and localisation. This study examined p14ARF and p53/Hdm2 expression and subcellular localisation by using immunohistochemistry in a series of invasive ductal breast cancers (IDCs) with concomitant ductal carcinoma in situ (DCIS), to evaluate whether findings in vitro were related to clinicopathological parameters such as HER-2 and their effect on patient outcome. METHODS: The 4C6 anti-p14ARF monoclonal antibody and Dako Envision Plus system were used to evaluate p14ARF expression in 103 patients; p53/Hdm2 staining was performed. RESULTS: p14ARF was evaluable in 96 patients, with nuclear p14ARF expression (modified Quick-score > or = 3) in 79% (n = 76) of IDCs and in associated DCIS in 74 patients. Cytoplasmic p14ARF was detectable in 23 breast cancers. Nuclear and cytoplasmic p14ARF showed no correlation with p53 subcellular immunoreactivity. Increasing levels of cytoplasmic p14ARF were associated with nuclear and cytoplasmic Hdm2 expression (P < 0.001). Subcellular ARF expression was not associated with clinicopathological parameters, and although not an independent prognosticator, these preliminary findings suggest that cytoplasmic p14ARF might be associated with a better overall survival (P = 0.09; log rank). The association between HER-2 positivity and nuclear p14ARF (P = 0.038), as well as nuclear Hdm2 (P = 0.019), reflects the in vitro findings of HER-2 interaction with the ARF/Hdm2 pathway. Cytoplasmic p53 and Hdm2 expression might have biological implications, through an association of cytoplasmic p53 with increased tumour proliferation (P = 0.005), and an improved overall survival (P = 0.002, log rank) in cytoplasmic Hdm2-expressing tumours, that independently predict favourable overall survival (P = 0.02) and disease-free survival (P = 0.03). CONCLUSIONS: Nuclear p14ARF expression is similar in IDCs and DCIS and is associated with Hdm2 immunoreactivity. Nuclear p14ARF and Hdm2 might be regulated by HER-2. Clearly, our findings in vivo suggest a complexity of p14ARF/Hdm2 and p53 pathways in which consideration of cytoplasmic p14ARF and Hdm2 might have tumorigenic implications. More... »

PAGES

r571-r585

References to SciGraph publications

  • 2001-10. The INK4a/ARF network in tumour suppression in NATURE REVIEWS MOLECULAR CELL BIOLOGY
  • 2001-11-01. utImmunohistochemical Detection of the Alternate INK4a-Encoded Tumor Suppressor Protein p14ARF in Archival Human Cancers and Cell Lines Using Commercial Antibodies: Correlation with p16INK4a Expression in MODERN PATHOLOGY
  • 2003-10-03. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis in BREAST CANCER RESEARCH
  • 2000-06-19. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization in ONCOGENE
  • 2000-02-10. Identification of a cryptic nucleolar-localization signal in MDM2 in NATURE CELL BIOLOGY
  • 2002-10-01. CORRESPONDENCE RE: GERADTS J, WILENTZ RE, ROBERTS H. IMMUNOHISTOCHEMICAL DETECTION OF THE ALTERNATE INK4A-ENCODED TUMOR SUPPRESSOR PROTEIN P14ARF IN ARCHIVAL HUMAN CANCERS AND CELL LINES USING COMMERCIAL ANTIBODIES: CORRELATION WITH P16INK4A EXPRESSION. MOD PATHOL 2001;14:1162–68. in MODERN PATHOLOGY
  • 1996-06. Abnormal expression of MDM-2 in breast carcinomas in BREAST CANCER RESEARCH AND TREATMENT
  • 2001-04-05. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus in NATURE CELL BIOLOGY
  • 1999-01. Functions of the MDM2 oncoprotein in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 1998-11-24. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression in ONCOGENE
  • 2000-05-15. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo in ONCOGENE
  • 2001-07. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer in ONCOGENE
  • 2001-08-28. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo in ONCOGENE
  • 2003-03-27. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice in ONCOGENE
  • 2001-10-08. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation in NATURE CELL BIOLOGY
  • 2004-01-20. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ in BRITISH JOURNAL OF CANCER
  • 1992-10. The Nottingham prognostic index in primary breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2000-10. The ins and outs of p53 in NATURE CELL BIOLOGY
  • 2000-03. p53: only ARF the story in NATURE CELL BIOLOGY
  • 2000-01-20. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function in ONCOGENE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/bcr912

    DOI

    http://dx.doi.org/10.1186/bcr912

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1048748154

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15318938


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Breast Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Ductal, Breast", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Intraductal, Noninfiltrating", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunohistochemistry", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nuclear Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prognosis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins c-mdm2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptor, ErbB-2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Suppressor Protein p14ARF", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Suppressor Protein p53", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "University of Bristol Division of Surgery, Bristol Royal Infirmary, Bristol, UK", 
              "id": "http://www.grid.ac/institutes/grid.418482.3", 
              "name": [
                "University of Bristol Division of Surgery, Bristol Royal Infirmary, Bristol, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vestey", 
            "givenName": "SB", 
            "id": "sg:person.0723152246.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723152246.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Histopathology, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, UK", 
              "id": "http://www.grid.ac/institutes/grid.418482.3", 
              "name": [
                "Department of Histopathology, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sen", 
            "givenName": "C", 
            "id": "sg:person.01037400646.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037400646.37"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Histopathology, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, UK", 
              "id": "http://www.grid.ac/institutes/grid.418482.3", 
              "name": [
                "Department of Histopathology, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Calder", 
            "givenName": "CJ", 
            "id": "sg:person.013665661120.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013665661120.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Bristol Division of Surgery, Bristol Royal Infirmary, Bristol, UK", 
              "id": "http://www.grid.ac/institutes/grid.418482.3", 
              "name": [
                "University of Bristol Division of Surgery, Bristol Royal Infirmary, Bristol, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Perks", 
            "givenName": "CM", 
            "id": "sg:person.01310676612.74", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310676612.74"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Histopathology, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, UK", 
              "id": "http://www.grid.ac/institutes/grid.418482.3", 
              "name": [
                "Department of Histopathology, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pignatelli", 
            "givenName": "M", 
            "id": "sg:person.0744316125.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744316125.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Bristol Division of Surgery, Bristol Royal Infirmary, Bristol, UK", 
              "id": "http://www.grid.ac/institutes/grid.418482.3", 
              "name": [
                "University of Bristol Division of Surgery, Bristol Royal Infirmary, Bristol, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Winters", 
            "givenName": "ZE", 
            "id": "sg:person.01210734101.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210734101.23"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/35096061", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028410796", 
              "https://doi.org/10.1038/35096061"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35004078", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005599935", 
              "https://doi.org/10.1038/35004078"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/bcr654", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021147050", 
              "https://doi.org/10.1186/bcr654"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203629", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044440060", 
              "https://doi.org/10.1038/sj.onc.1203629"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/modpathol.3880452", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020289213", 
              "https://doi.org/10.1038/modpathol.3880452"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/modpathol.3880662", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042922314", 
              "https://doi.org/10.1038/modpathol.3880662"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1202501", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006478543", 
              "https://doi.org/10.1038/sj.onc.1202501"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01840834", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032983382", 
              "https://doi.org/10.1007/bf01840834"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203593", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031554726", 
              "https://doi.org/10.1038/sj.onc.1203593"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35036427", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027151177", 
              "https://doi.org/10.1038/35036427"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35004057", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000693111", 
              "https://doi.org/10.1038/35004057"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s000180050273", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012299018", 
              "https://doi.org/10.1007/s000180050273"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01806499", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022793933", 
              "https://doi.org/10.1007/bf01806499"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1204656", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044764418", 
              "https://doi.org/10.1038/sj.onc.1204656"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203262", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031110147", 
              "https://doi.org/10.1038/sj.onc.1203262"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35074506", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008884225", 
              "https://doi.org/10.1038/35074506"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6601534", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012589116", 
              "https://doi.org/10.1038/sj.bjc.6601534"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206303", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043009363", 
              "https://doi.org/10.1038/sj.onc.1206303"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncb1101-973", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047316229", 
              "https://doi.org/10.1038/ncb1101-973"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1204617", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007401365", 
              "https://doi.org/10.1038/sj.onc.1204617"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-07-29", 
        "datePublishedReg": "2004-07-29", 
        "description": "INTRODUCTION: p14ARF stabilises nuclear p53, with a variable expression of p14ARF mRNA in breast cancers. In vitro, nuclear p14ARF binds Hdm2 to block Hdm2-dependent nucleocytoplasmic shuttling of p53, which is required before cytoplasmic degradation of p53. p14ARF is negatively regulated by p53 and through p53-independent pathways. No studies have yet examined levels of p14ARF protein expression in breast cancer and their relationship to Hdm2/p53 immunoreactivity or subcellular localisation. Previously, immunohistochemical expression of cytoplasmic p14ARF, p53 and Hdm2 has been described. HER-2 (c-erbB2/neu) predicts prognosis and interacts with the p14ARF/Hdm2 pathway to inactivate p14ARF and to influence Hdm2 activity and localisation. This study examined p14ARF and p53/Hdm2 expression and subcellular localisation by using immunohistochemistry in a series of invasive ductal breast cancers (IDCs) with concomitant ductal carcinoma in situ (DCIS), to evaluate whether findings in vitro were related to clinicopathological parameters such as HER-2 and their effect on patient outcome.\nMETHODS: The 4C6 anti-p14ARF monoclonal antibody and Dako Envision Plus system were used to evaluate p14ARF expression in 103 patients; p53/Hdm2 staining was performed.\nRESULTS: p14ARF was evaluable in 96 patients, with nuclear p14ARF expression (modified Quick-score > or = 3) in 79% (n = 76) of IDCs and in associated DCIS in 74 patients. Cytoplasmic p14ARF was detectable in 23 breast cancers. Nuclear and cytoplasmic p14ARF showed no correlation with p53 subcellular immunoreactivity. Increasing levels of cytoplasmic p14ARF were associated with nuclear and cytoplasmic Hdm2 expression (P < 0.001). Subcellular ARF expression was not associated with clinicopathological parameters, and although not an independent prognosticator, these preliminary findings suggest that cytoplasmic p14ARF might be associated with a better overall survival (P = 0.09; log rank). The association between HER-2 positivity and nuclear p14ARF (P = 0.038), as well as nuclear Hdm2 (P = 0.019), reflects the in vitro findings of HER-2 interaction with the ARF/Hdm2 pathway. Cytoplasmic p53 and Hdm2 expression might have biological implications, through an association of cytoplasmic p53 with increased tumour proliferation (P = 0.005), and an improved overall survival (P = 0.002, log rank) in cytoplasmic Hdm2-expressing tumours, that independently predict favourable overall survival (P = 0.02) and disease-free survival (P = 0.03).\nCONCLUSIONS: Nuclear p14ARF expression is similar in IDCs and DCIS and is associated with Hdm2 immunoreactivity. Nuclear p14ARF and Hdm2 might be regulated by HER-2. Clearly, our findings in vivo suggest a complexity of p14ARF/Hdm2 and p53 pathways in which consideration of cytoplasmic p14ARF and Hdm2 might have tumorigenic implications.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/bcr912", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1022375", 
            "issn": [
              "1465-5411", 
              "1465-542X"
            ], 
            "name": "Breast Cancer Research", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "6"
          }
        ], 
        "keywords": [
          "invasive ductal breast cancer", 
          "breast cancer", 
          "overall survival", 
          "ductal carcinoma", 
          "p14ARF expression", 
          "clinicopathological parameters", 
          "HDM2 expression", 
          "concomitant ductal carcinoma", 
          "improved overall survival", 
          "disease-free survival", 
          "ductal breast cancer", 
          "better overall survival", 
          "invasive breast cancer", 
          "favorable overall survival", 
          "p14ARF protein expression", 
          "cytoplasmic p53", 
          "independent prognosticator", 
          "p53-independent pathway", 
          "patient outcomes", 
          "HER-2", 
          "immunohistochemical expression", 
          "p53 immunoreactivity", 
          "tumor proliferation", 
          "p14ARF mRNA", 
          "cancer", 
          "patients", 
          "monoclonal antibodies", 
          "immunoreactivity", 
          "protein expression", 
          "nuclear p53", 
          "p53 pathway", 
          "survival", 
          "DCIS", 
          "p53", 
          "Hdm2 activity", 
          "variable expression", 
          "carcinoma", 
          "p14ARF", 
          "preliminary findings", 
          "Plus system", 
          "ARF expression", 
          "expression", 
          "subcellular localisation", 
          "HDM2", 
          "association", 
          "findings", 
          "pathway", 
          "prognosticator", 
          "prognosis", 
          "immunohistochemistry", 
          "tumors", 
          "positivity", 
          "antibodies", 
          "cytoplasmic degradation", 
          "staining", 
          "localisation", 
          "outcomes", 
          "levels", 
          "vitro", 
          "vivo", 
          "study", 
          "proliferation", 
          "mRNA", 
          "activity", 
          "biological implications", 
          "correlation", 
          "nucleocytoplasmic shuttling", 
          "effect", 
          "implications", 
          "relationship", 
          "series", 
          "situ", 
          "shuttling", 
          "parameters", 
          "consideration", 
          "interaction", 
          "system", 
          "degradation", 
          "complexity", 
          "nuclear p14ARF binds Hdm2", 
          "p14ARF binds Hdm2", 
          "binds Hdm2", 
          "Hdm2-dependent nucleocytoplasmic shuttling", 
          "Hdm2/p53 immunoreactivity", 
          "cytoplasmic p14ARF", 
          "p14ARF/Hdm2 pathway", 
          "Hdm2 pathway", 
          "p53/Hdm2 expression", 
          "anti-p14ARF monoclonal antibody", 
          "Dako Envision Plus system", 
          "Envision Plus system", 
          "p53/Hdm2 staining", 
          "Hdm2 staining", 
          "nuclear p14ARF expression", 
          "p53 subcellular immunoreactivity", 
          "subcellular immunoreactivity", 
          "cytoplasmic Hdm2 expression", 
          "Subcellular ARF expression", 
          "nuclear p14ARF", 
          "nuclear Hdm2", 
          "ARF/Hdm2 pathway", 
          "cytoplasmic Hdm2", 
          "Hdm2 immunoreactivity", 
          "p14ARF/Hdm2", 
          "tumorigenic implications"
        ], 
        "name": "p14ARF expression in invasive breast cancers and ductal carcinoma in situ \u2013 relationships to p53 and Hdm2", 
        "pagination": "r571-r585", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1048748154"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/bcr912"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15318938"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/bcr912", 
          "https://app.dimensions.ai/details/publication/pub.1048748154"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:16", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_393.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/bcr912"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/bcr912'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/bcr912'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/bcr912'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/bcr912'


     

    This table displays all metadata directly associated to this object as RDF triples.

    352 TRIPLES      22 PREDICATES      168 URIs      140 LITERALS      24 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/bcr912 schema:about N28556daba02b449dba26d4f510ff861a
    2 N3a8305775fed43e38f4cad3f6363a2d2
    3 N3ec1c57e2bdc46f69d6de268e19e838b
    4 N41c23af2298e47b5a1fd4194aaceaa37
    5 N474cbfcf145a4741a0244b191c2f99a6
    6 N6426cf620c114de9a1408013ec05893b
    7 N720c42063a0642fbb9c4c778d979fec3
    8 N83d0080e1e9345f59068d75d77f6e87f
    9 N84a7374a511449d1be57256fc5c63a27
    10 N8b25289f7bed49e7bbb91a4ae9b11702
    11 N97e8a10bb9424f34858ca33d1ff1fd10
    12 Na5b206ceb19449e1aa5bf05eb3b0a81d
    13 Nbd49c4765bd341ef9440c9ef6ca8343a
    14 Nccc0f1ab623446ffa22fd056801589c1
    15 Ne467f86b2c274acdb8f2c264993b3c93
    16 Ne7405acb19db4688b4b4352e6cbc29eb
    17 Ned3eb8f357ba44e29c7dd4a8fa40dbba
    18 anzsrc-for:11
    19 anzsrc-for:1112
    20 schema:author Ndd7f8a21d59642aa9bce82740bc08424
    21 schema:citation sg:pub.10.1007/bf01806499
    22 sg:pub.10.1007/bf01840834
    23 sg:pub.10.1007/s000180050273
    24 sg:pub.10.1038/35004057
    25 sg:pub.10.1038/35004078
    26 sg:pub.10.1038/35036427
    27 sg:pub.10.1038/35074506
    28 sg:pub.10.1038/35096061
    29 sg:pub.10.1038/modpathol.3880452
    30 sg:pub.10.1038/modpathol.3880662
    31 sg:pub.10.1038/ncb1101-973
    32 sg:pub.10.1038/sj.bjc.6601534
    33 sg:pub.10.1038/sj.onc.1202501
    34 sg:pub.10.1038/sj.onc.1203262
    35 sg:pub.10.1038/sj.onc.1203593
    36 sg:pub.10.1038/sj.onc.1203629
    37 sg:pub.10.1038/sj.onc.1204617
    38 sg:pub.10.1038/sj.onc.1204656
    39 sg:pub.10.1038/sj.onc.1206303
    40 sg:pub.10.1186/bcr654
    41 schema:datePublished 2004-07-29
    42 schema:datePublishedReg 2004-07-29
    43 schema:description INTRODUCTION: p14ARF stabilises nuclear p53, with a variable expression of p14ARF mRNA in breast cancers. In vitro, nuclear p14ARF binds Hdm2 to block Hdm2-dependent nucleocytoplasmic shuttling of p53, which is required before cytoplasmic degradation of p53. p14ARF is negatively regulated by p53 and through p53-independent pathways. No studies have yet examined levels of p14ARF protein expression in breast cancer and their relationship to Hdm2/p53 immunoreactivity or subcellular localisation. Previously, immunohistochemical expression of cytoplasmic p14ARF, p53 and Hdm2 has been described. HER-2 (c-erbB2/neu) predicts prognosis and interacts with the p14ARF/Hdm2 pathway to inactivate p14ARF and to influence Hdm2 activity and localisation. This study examined p14ARF and p53/Hdm2 expression and subcellular localisation by using immunohistochemistry in a series of invasive ductal breast cancers (IDCs) with concomitant ductal carcinoma in situ (DCIS), to evaluate whether findings in vitro were related to clinicopathological parameters such as HER-2 and their effect on patient outcome. METHODS: The 4C6 anti-p14ARF monoclonal antibody and Dako Envision Plus system were used to evaluate p14ARF expression in 103 patients; p53/Hdm2 staining was performed. RESULTS: p14ARF was evaluable in 96 patients, with nuclear p14ARF expression (modified Quick-score > or = 3) in 79% (n = 76) of IDCs and in associated DCIS in 74 patients. Cytoplasmic p14ARF was detectable in 23 breast cancers. Nuclear and cytoplasmic p14ARF showed no correlation with p53 subcellular immunoreactivity. Increasing levels of cytoplasmic p14ARF were associated with nuclear and cytoplasmic Hdm2 expression (P < 0.001). Subcellular ARF expression was not associated with clinicopathological parameters, and although not an independent prognosticator, these preliminary findings suggest that cytoplasmic p14ARF might be associated with a better overall survival (P = 0.09; log rank). The association between HER-2 positivity and nuclear p14ARF (P = 0.038), as well as nuclear Hdm2 (P = 0.019), reflects the in vitro findings of HER-2 interaction with the ARF/Hdm2 pathway. Cytoplasmic p53 and Hdm2 expression might have biological implications, through an association of cytoplasmic p53 with increased tumour proliferation (P = 0.005), and an improved overall survival (P = 0.002, log rank) in cytoplasmic Hdm2-expressing tumours, that independently predict favourable overall survival (P = 0.02) and disease-free survival (P = 0.03). CONCLUSIONS: Nuclear p14ARF expression is similar in IDCs and DCIS and is associated with Hdm2 immunoreactivity. Nuclear p14ARF and Hdm2 might be regulated by HER-2. Clearly, our findings in vivo suggest a complexity of p14ARF/Hdm2 and p53 pathways in which consideration of cytoplasmic p14ARF and Hdm2 might have tumorigenic implications.
    44 schema:genre article
    45 schema:inLanguage en
    46 schema:isAccessibleForFree true
    47 schema:isPartOf N136397a9abf944d2b722b4b8d0b7a674
    48 N3c387b70b07948218f4f4719c55d3d4d
    49 sg:journal.1022375
    50 schema:keywords ARF expression
    51 ARF/Hdm2 pathway
    52 DCIS
    53 Dako Envision Plus system
    54 Envision Plus system
    55 HDM2
    56 HDM2 expression
    57 HER-2
    58 Hdm2 activity
    59 Hdm2 immunoreactivity
    60 Hdm2 pathway
    61 Hdm2 staining
    62 Hdm2-dependent nucleocytoplasmic shuttling
    63 Hdm2/p53 immunoreactivity
    64 Plus system
    65 Subcellular ARF expression
    66 activity
    67 anti-p14ARF monoclonal antibody
    68 antibodies
    69 association
    70 better overall survival
    71 binds Hdm2
    72 biological implications
    73 breast cancer
    74 cancer
    75 carcinoma
    76 clinicopathological parameters
    77 complexity
    78 concomitant ductal carcinoma
    79 consideration
    80 correlation
    81 cytoplasmic Hdm2
    82 cytoplasmic Hdm2 expression
    83 cytoplasmic degradation
    84 cytoplasmic p14ARF
    85 cytoplasmic p53
    86 degradation
    87 disease-free survival
    88 ductal breast cancer
    89 ductal carcinoma
    90 effect
    91 expression
    92 favorable overall survival
    93 findings
    94 immunohistochemical expression
    95 immunohistochemistry
    96 immunoreactivity
    97 implications
    98 improved overall survival
    99 independent prognosticator
    100 interaction
    101 invasive breast cancer
    102 invasive ductal breast cancer
    103 levels
    104 localisation
    105 mRNA
    106 monoclonal antibodies
    107 nuclear Hdm2
    108 nuclear p14ARF
    109 nuclear p14ARF binds Hdm2
    110 nuclear p14ARF expression
    111 nuclear p53
    112 nucleocytoplasmic shuttling
    113 outcomes
    114 overall survival
    115 p14ARF
    116 p14ARF binds Hdm2
    117 p14ARF expression
    118 p14ARF mRNA
    119 p14ARF protein expression
    120 p14ARF/Hdm2
    121 p14ARF/Hdm2 pathway
    122 p53
    123 p53 immunoreactivity
    124 p53 pathway
    125 p53 subcellular immunoreactivity
    126 p53-independent pathway
    127 p53/Hdm2 expression
    128 p53/Hdm2 staining
    129 parameters
    130 pathway
    131 patient outcomes
    132 patients
    133 positivity
    134 preliminary findings
    135 prognosis
    136 prognosticator
    137 proliferation
    138 protein expression
    139 relationship
    140 series
    141 shuttling
    142 situ
    143 staining
    144 study
    145 subcellular immunoreactivity
    146 subcellular localisation
    147 survival
    148 system
    149 tumor proliferation
    150 tumorigenic implications
    151 tumors
    152 variable expression
    153 vitro
    154 vivo
    155 schema:name p14ARF expression in invasive breast cancers and ductal carcinoma in situ – relationships to p53 and Hdm2
    156 schema:pagination r571-r585
    157 schema:productId N09c2b7a4ef1e42e7a79a8c5d5b009a42
    158 N98c90f5bffcf42bdb4a6e5161cb1cfcd
    159 Na77adc6b58064cc6930d51a5aaf574b7
    160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048748154
    161 https://doi.org/10.1186/bcr912
    162 schema:sdDatePublished 2021-12-01T19:16
    163 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    164 schema:sdPublisher N868ca1b38d27404187b42a886929ba2c
    165 schema:url https://doi.org/10.1186/bcr912
    166 sgo:license sg:explorer/license/
    167 sgo:sdDataset articles
    168 rdf:type schema:ScholarlyArticle
    169 N006cc1a1980f42b08b7b35a0c8cbe42f rdf:first sg:person.0744316125.39
    170 rdf:rest N6745a080566c40c1bd2b8850f8d0d642
    171 N09c2b7a4ef1e42e7a79a8c5d5b009a42 schema:name pubmed_id
    172 schema:value 15318938
    173 rdf:type schema:PropertyValue
    174 N136397a9abf944d2b722b4b8d0b7a674 schema:volumeNumber 6
    175 rdf:type schema:PublicationVolume
    176 N28556daba02b449dba26d4f510ff861a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Humans
    178 rdf:type schema:DefinedTerm
    179 N3a8305775fed43e38f4cad3f6363a2d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    180 schema:name Survival Analysis
    181 rdf:type schema:DefinedTerm
    182 N3c387b70b07948218f4f4719c55d3d4d schema:issueNumber 5
    183 rdf:type schema:PublicationIssue
    184 N3ec1c57e2bdc46f69d6de268e19e838b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Immunohistochemistry
    186 rdf:type schema:DefinedTerm
    187 N41c23af2298e47b5a1fd4194aaceaa37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Middle Aged
    189 rdf:type schema:DefinedTerm
    190 N474cbfcf145a4741a0244b191c2f99a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Prognosis
    192 rdf:type schema:DefinedTerm
    193 N5dba38ff9d0d412795e3dbbf1ee7c6db rdf:first sg:person.013665661120.28
    194 rdf:rest Ne04dcd9fee8040a8a012f2a1d0d525a1
    195 N6426cf620c114de9a1408013ec05893b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Receptor, ErbB-2
    197 rdf:type schema:DefinedTerm
    198 N6745a080566c40c1bd2b8850f8d0d642 rdf:first sg:person.01210734101.23
    199 rdf:rest rdf:nil
    200 N720c42063a0642fbb9c4c778d979fec3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    201 schema:name Nuclear Proteins
    202 rdf:type schema:DefinedTerm
    203 N83d0080e1e9345f59068d75d77f6e87f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    204 schema:name Carcinoma, Ductal, Breast
    205 rdf:type schema:DefinedTerm
    206 N84a7374a511449d1be57256fc5c63a27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    207 schema:name Aged
    208 rdf:type schema:DefinedTerm
    209 N85500816bebb4402bb1d69337b49db67 rdf:first sg:person.01037400646.37
    210 rdf:rest N5dba38ff9d0d412795e3dbbf1ee7c6db
    211 N868ca1b38d27404187b42a886929ba2c schema:name Springer Nature - SN SciGraph project
    212 rdf:type schema:Organization
    213 N8b25289f7bed49e7bbb91a4ae9b11702 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    214 schema:name Proto-Oncogene Proteins c-mdm2
    215 rdf:type schema:DefinedTerm
    216 N97e8a10bb9424f34858ca33d1ff1fd10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    217 schema:name Adult
    218 rdf:type schema:DefinedTerm
    219 N98c90f5bffcf42bdb4a6e5161cb1cfcd schema:name dimensions_id
    220 schema:value pub.1048748154
    221 rdf:type schema:PropertyValue
    222 Na5b206ceb19449e1aa5bf05eb3b0a81d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Proto-Oncogene Proteins
    224 rdf:type schema:DefinedTerm
    225 Na77adc6b58064cc6930d51a5aaf574b7 schema:name doi
    226 schema:value 10.1186/bcr912
    227 rdf:type schema:PropertyValue
    228 Nbd49c4765bd341ef9440c9ef6ca8343a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    229 schema:name Breast Neoplasms
    230 rdf:type schema:DefinedTerm
    231 Nccc0f1ab623446ffa22fd056801589c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    232 schema:name Carcinoma, Intraductal, Noninfiltrating
    233 rdf:type schema:DefinedTerm
    234 Ndd7f8a21d59642aa9bce82740bc08424 rdf:first sg:person.0723152246.32
    235 rdf:rest N85500816bebb4402bb1d69337b49db67
    236 Ne04dcd9fee8040a8a012f2a1d0d525a1 rdf:first sg:person.01310676612.74
    237 rdf:rest N006cc1a1980f42b08b7b35a0c8cbe42f
    238 Ne467f86b2c274acdb8f2c264993b3c93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    239 schema:name Tumor Suppressor Protein p53
    240 rdf:type schema:DefinedTerm
    241 Ne7405acb19db4688b4b4352e6cbc29eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    242 schema:name Tumor Suppressor Protein p14ARF
    243 rdf:type schema:DefinedTerm
    244 Ned3eb8f357ba44e29c7dd4a8fa40dbba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    245 schema:name Aged, 80 and over
    246 rdf:type schema:DefinedTerm
    247 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    248 schema:name Medical and Health Sciences
    249 rdf:type schema:DefinedTerm
    250 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    251 schema:name Oncology and Carcinogenesis
    252 rdf:type schema:DefinedTerm
    253 sg:journal.1022375 schema:issn 1465-5411
    254 1465-542X
    255 schema:name Breast Cancer Research
    256 schema:publisher Springer Nature
    257 rdf:type schema:Periodical
    258 sg:person.01037400646.37 schema:affiliation grid-institutes:grid.418482.3
    259 schema:familyName Sen
    260 schema:givenName C
    261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037400646.37
    262 rdf:type schema:Person
    263 sg:person.01210734101.23 schema:affiliation grid-institutes:grid.418482.3
    264 schema:familyName Winters
    265 schema:givenName ZE
    266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210734101.23
    267 rdf:type schema:Person
    268 sg:person.01310676612.74 schema:affiliation grid-institutes:grid.418482.3
    269 schema:familyName Perks
    270 schema:givenName CM
    271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310676612.74
    272 rdf:type schema:Person
    273 sg:person.013665661120.28 schema:affiliation grid-institutes:grid.418482.3
    274 schema:familyName Calder
    275 schema:givenName CJ
    276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013665661120.28
    277 rdf:type schema:Person
    278 sg:person.0723152246.32 schema:affiliation grid-institutes:grid.418482.3
    279 schema:familyName Vestey
    280 schema:givenName SB
    281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723152246.32
    282 rdf:type schema:Person
    283 sg:person.0744316125.39 schema:affiliation grid-institutes:grid.418482.3
    284 schema:familyName Pignatelli
    285 schema:givenName M
    286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744316125.39
    287 rdf:type schema:Person
    288 sg:pub.10.1007/bf01806499 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022793933
    289 https://doi.org/10.1007/bf01806499
    290 rdf:type schema:CreativeWork
    291 sg:pub.10.1007/bf01840834 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032983382
    292 https://doi.org/10.1007/bf01840834
    293 rdf:type schema:CreativeWork
    294 sg:pub.10.1007/s000180050273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012299018
    295 https://doi.org/10.1007/s000180050273
    296 rdf:type schema:CreativeWork
    297 sg:pub.10.1038/35004057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000693111
    298 https://doi.org/10.1038/35004057
    299 rdf:type schema:CreativeWork
    300 sg:pub.10.1038/35004078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005599935
    301 https://doi.org/10.1038/35004078
    302 rdf:type schema:CreativeWork
    303 sg:pub.10.1038/35036427 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027151177
    304 https://doi.org/10.1038/35036427
    305 rdf:type schema:CreativeWork
    306 sg:pub.10.1038/35074506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008884225
    307 https://doi.org/10.1038/35074506
    308 rdf:type schema:CreativeWork
    309 sg:pub.10.1038/35096061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028410796
    310 https://doi.org/10.1038/35096061
    311 rdf:type schema:CreativeWork
    312 sg:pub.10.1038/modpathol.3880452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020289213
    313 https://doi.org/10.1038/modpathol.3880452
    314 rdf:type schema:CreativeWork
    315 sg:pub.10.1038/modpathol.3880662 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042922314
    316 https://doi.org/10.1038/modpathol.3880662
    317 rdf:type schema:CreativeWork
    318 sg:pub.10.1038/ncb1101-973 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047316229
    319 https://doi.org/10.1038/ncb1101-973
    320 rdf:type schema:CreativeWork
    321 sg:pub.10.1038/sj.bjc.6601534 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012589116
    322 https://doi.org/10.1038/sj.bjc.6601534
    323 rdf:type schema:CreativeWork
    324 sg:pub.10.1038/sj.onc.1202501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006478543
    325 https://doi.org/10.1038/sj.onc.1202501
    326 rdf:type schema:CreativeWork
    327 sg:pub.10.1038/sj.onc.1203262 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031110147
    328 https://doi.org/10.1038/sj.onc.1203262
    329 rdf:type schema:CreativeWork
    330 sg:pub.10.1038/sj.onc.1203593 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031554726
    331 https://doi.org/10.1038/sj.onc.1203593
    332 rdf:type schema:CreativeWork
    333 sg:pub.10.1038/sj.onc.1203629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044440060
    334 https://doi.org/10.1038/sj.onc.1203629
    335 rdf:type schema:CreativeWork
    336 sg:pub.10.1038/sj.onc.1204617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007401365
    337 https://doi.org/10.1038/sj.onc.1204617
    338 rdf:type schema:CreativeWork
    339 sg:pub.10.1038/sj.onc.1204656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044764418
    340 https://doi.org/10.1038/sj.onc.1204656
    341 rdf:type schema:CreativeWork
    342 sg:pub.10.1038/sj.onc.1206303 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043009363
    343 https://doi.org/10.1038/sj.onc.1206303
    344 rdf:type schema:CreativeWork
    345 sg:pub.10.1186/bcr654 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021147050
    346 https://doi.org/10.1186/bcr654
    347 rdf:type schema:CreativeWork
    348 grid-institutes:grid.418482.3 schema:alternateName Department of Histopathology, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, UK
    349 University of Bristol Division of Surgery, Bristol Royal Infirmary, Bristol, UK
    350 schema:name Department of Histopathology, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, UK
    351 University of Bristol Division of Surgery, Bristol Royal Infirmary, Bristol, UK
    352 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...